Which is the most cost-effective combination therapy strategy using interferon α-2b plus ribavirin for naïve patients with chronic hepatitis C?

Clinical Drug Investigation

Volumn 22, Issue 1, 2002, Pages 31-39

  Buti, Maria ^a   Casado, Miguel A ^b   Fosbrook, Leslie ^b   Esteban, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Schering Plough   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENOTYPE; HEALTH CARE SYSTEM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SPAIN; STANDARD; STATISTICAL MODEL; VIRUS EXAMINATION;

EID: 0036177614     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222010-00005     Document Type: Article

References (20)

1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. EASL International Consensus Conference on Hepatitis C
4. Cost-effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
5. Is an 'a la carte' combination of interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
6. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C
7. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C
8. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C
9. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C
10. Coste-efectividad de la hepatitis crónica C con interferon alfa
11. The decision rules of cost-effectiveness analysis
12. Long-term course of interferon-treated chronic hepatitis C
13. 10-Year follow-up after interferon-α therapy for chronic hepatitis C
14. Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
15. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
16. The cost-effectiveness of combination antiretroviral therapy for HIV disease
17. Estimating future hepatitis C morbidity, mortality and costs in the United States
18. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
19. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis